Zenodo (CERN European Organization for Nuclear Research)
September 2, 2026
Andrea Vittorini
preprint
This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather...
Biological Psychiatry Global Open Science
September 1, 2026
Elizabeth A Virakorn, Kathryn Baker, Nicholas A. Everett et al.
Background Recent work suggests that psilocybin, a hallucinogenic 5-HT 2A R agonist with rapid and long-lasting anti-depressant actions, facilitates fear extinction retention in adult rodents. However, psilocybin’s effects on adolescent fear extinction are unknown. Further, chronic stress in adolescence predisposes individuals to developing psychopathologies such as anxiety and fear-related...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Kusudo, K Yonezawa, Sota Tomiyama et al.
Abstract Background Psilocybin, a prodrug metabolized to psilocin, a serotonin 2A receptor agonist, has reemerged as a promising therapeutic option for treatment-resistant depression (TRD). Clinical trials conducted mainly in North America and Europe have demonstrated that psilocybin administered with psychological support can produce rapid and sustained antidepressant effects with favorable...
The International Journal of Neuropsychopharmacology
September 1, 2026
Christopher Sheridan, Guillaume Thuery, K Brennan et al.
Abstract Background Serotonergic psychedelics have recently re-emerged as promising therapeutic agents in psychiatry, showing positive outcomes in clinical trials for treatment-resistant depression, major depression, and PTSD. However, their effects on the immune system are poorly characterized. It remains unclear whether these compounds exert immunomodulatory effects that contribute to their...
The International Journal of Neuropsychopharmacology
September 1, 2026
Jessica Mingardi, Stefano Spinosa, Noemi Nicosia et al.
Abstract Background Stress is a recognized risk factor for developmental and adult psychiatric disorders. Indeed, stressful events, particularly during the first phases of life, such as trauma, neglect or abuse, have been associated with increased psychiatric risk over the course of a lifetime, although with some sex-differences. Indeed, the biological sex shapes the stress response impacting...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Yonezawa, K Kusudo, Sota Tomiyama et al.
Abstract Background Despite recent advances in the treatment of major depression, approximately 30% of patients show insufficient improvement with conventional antidepressants, a condition commonly referred to as treatment-resistant depression (TRD). Psilocybin is a classic psychedelic compound that has received renewed attention as a promising therapeutic candidate for TRD. Clinical trials...
The International Journal of Neuropsychopharmacology
September 1, 2026
Ella Nield, Martha López-canul, Antonio Inserra et al.
Abstract Background Pain conditions are major health problems resulting in physical, psychological and social impairment (1), and health care costs (2,3). Within the last decade, research has demonstrated that 5-HT2A agonists including psilocybin and LSD elicit spiritual experiences (4) and functional connectivity changes between diverse brain areas (5). Therefore, it is pertinent to...
Neuroscience Research
September 1, 2026
Mersedeh Shamsedin
ABSTRACT Background Fronto-hippocampal desynchronization is linked to cognitive decline in Alzheimer's-like pathology, but whether psilocybin can restore this dysfunction is unknown. Methods Male rats received intracerebroventricular streptozotocin (ICV-STZ) to induce neurotoxicity, followed by a single dose of psilocybin (2.5 mg/kg, the maximum tolerated dose). Spatial memory, recognition...
Acta Crystallographica. Section E, Crystallographic Communications
September 1, 2026
Marilyn Naeem, Andrew R Chadeayne, James A. Golen et al.
The solid-state structures of N-ethyl-4-hy-droxy-tryptamine (4-HO-NET) {systematic name: 3-[2-(ethyl-amino)-eth-yl]-1H-indol-4-ol}, C12H16N2O, and 4-hy-droxy-N-propyl-tryptamine (4-HO-NPT) {systematic name: 3-[2-(propyl-amino)-eth-yl]-1H-indol-4-ol}, C13H18N2O, are reported. Both compounds possess a single tryptamine mol-ecule in the asymmetric unit that exhibits an inter-nal O-H⋯N hydrogen...
Human Psychopharmacology: Clinical and Experimental
September 1, 2026
José Norberto Vásquez-Bonilla
OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A...
Journal of Psychoactive Drugs
September 1, 2026
Brian P. Meier, Courtney M. Lappas, Matthew W. Johnson
= 1,102), we examined the intentions to use psilocybin in a mental health context in relation to psychotherapy, psychiatric medication, and natural versus synthetic options. We also examined potential predictors of the intentions to use psilocybin. In Study 1, we found that participants had significantly lower intentions to use psilocybin in a mental health context versus psychotherapy and...
Psychiatry International
September 1, 2026
Damian Swieczkowski, Michal Pruc, Lukasz Szarpak et al.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) continue to drive interest in ketamine-family compounds and psilocybin, but antidepressant efficacy alone does not establish whether these interventions can be evaluated reliably or implemented responsibly. We conducted a structured narrative review using targeted PubMed/MEDLINE searches through 21 July 2026,...
Frontiers in Psychiatry
September 1, 2026
Gabrielle Agin-Liebes, Sarah Shnayder, Geena Fram et al.
Introduction Psilocybin treatment has shown promise for treatment-resistant obsessive-compulsive disorder (OCD), yet clinical response is variable. Little is known about the subjective experiences associated with divergent outcomes or the psychological processes differentiating responders from non-responders. Materials and methods A qualitative case comparison was conducted using...
Neuropsychopharmacology Reports
September 1, 2026
Daisuke Ibi, Rika Takaba, Keisuke Yoshida et al.
Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), and...
International Journal of Innovative Technologies in Social Science
August 31, 2026
Katarzyna Pawłucka, Aleksandra Pawlucka, Joanna Kadłuczka et al.
Objectives: This narrative review synthesizes current evidence regarding the modulation of psilocybin responsivity by female sex hormones (estrogen, progesterone, testosterone) across the lifespan, aiming to identify molecular mechanisms, clinical implications, and critical knowledge gaps for personalized psychedelic medicine. Methods: Databases including PubMed, ClinicalTrials.gov, and ANZCTR...
Zenodo (CERN European Organization for Nuclear Research)
August 31, 2026
preprint
Evidence for psilocybin use in chronic depression is limited, primarily focusing on treatment-resistant cases. While promising results have been noted in studies, more targeted and extensive research is needed.
Psychoactives
August 30, 2026
Laura Schäffert, Human-Friedrich Unterrainer
Background: Alcohol use disorder (AUD) remains a leading contributor to global morbidity, yet conventional treatments often yield suboptimal outcomes and high relapse rates. Psilocybin-assisted therapy has re-emerged as a potential intervention for substance use disorders, but its effectiveness and safety in AUD specifically remain to be comprehensively evaluated. Objective: To review and...
Journal of Psychopharmacology
August 30, 2026
Tiffini N Lovell, Peter B James, Skylar L Hodgins et al.
Fentanyl is the leading cause of fatal overdoses worldwide, and repeated use may lead to substance use disorder (SUD). In SUD, drug-associated contexts can trigger reward-related behavior even in the absence of the drug. Psychedelic compounds may weaken context-drug associations, reducing reward-related behavior to fentanyl. We evaluated the effects of the psychedelic psilocin and its...
Journal of Psychopharmacology
August 29, 2026
Marlene Tai, Balázs Szigeti, Amanda E. Downey et al.
BACKGROUND Psilocybin, a serotonergic psychedelic found in hallucinogenic mushrooms, is metabolized to psilocin, the compound responsible for its psychoactive effects. Psilocybin has demonstrated therapeutic potential for neuropsychiatric conditions. While recent trials have primarily used orally administered synthetic psilocybin, alternative formulations and delivery methods may offer...
Zenodo (CERN European Organization for Nuclear Research)
August 28, 2026
Luna da Silva Nascimento
preprint
Independent secondary computational research conducted on open-access longitudinal fMRI data (OpenNeuro ds006072). Preprint deposited on Zenodo. Full reproducible Riemannian pipeline available on GitLab.